Although a potential synergistic therapeutic effect of HDAC inhibition together with EGFR inhibition against EGFR inhibitor-resistant NSCLC cell lines has been reported in many studies, the mechanisms are unclear. Here, EGFR is linked to non-small cell lung carcinoma.